Over the past 12 months, shares of Amarin (NASDAQ:AMRN) have dropped 45% amid uncertainty around Vascepa's NCE status, buyout speculation that never came to fruition, and question marks around the efficacy of fish oil. The company is hoping to get expanded approval for Vascepa and announced today that the FDA's advisory committee meeting date has been set. In the following video, health-care analyst Max Macaluso discusses the importance of this meeting and the risks and opportunities up ahead for this speculative biotech.
Max Macaluso, Ph.D., and The Motley Fool have no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.